Significant Ownership of Lara Sullivan

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Lara Sullivan focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Lara Sullivan - Lara Sullivan, President,Chief Executive Officer & Chief Medical Officer
Manager location
Rockville, MD

Follow Filing Activity

Follow Lara Sullivan and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of Lara Sullivan

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PYXS Pyxis Oncology, Inc. Common Stock, par value $0.001 per share 11% $7,844,727 +$955,040 7,543,007 +14% Lara Sullivan, M.D. 31 Mar 2025

Schedules 13D/G Reported by Lara Sullivan:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .